One area of research is dual agonists that target both GLP-1 and glucagon receptors that have the potential to provide enhanced metabolic benefits and more significant weight reduction
New England Journal of Medicine, 384 (11), 9891002
WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications (4)]
Its action on GIP receptors enhances insulin release to help manage blood sugar levels
Reported incidences included nausea (5.922.2%), diarrhea (8.825.3%), vomiting (2.99.1%), and constipation (8.816.2%), with discontinuation rates reaching 19% in high-dose monthly regimens (816 mg) [62,63,64]
Semaglutide, like any medication, comes with its own set of potential side effects